Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert K Stuart

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Experimental Hematology|September 30, 2009
Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemiaKeisuke Shirai, Yasuhiko Sera, William Bulkeley, et al.
Transfusion|March 12, 2011
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft functionErin T Alexander, Jeanne A Towery, Ashley N Miller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2015
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumorsJason M God, Christine Cameron, Janette Figueroa, et al.
Blood|December 21, 2006
Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNAYoko Otake, Sridharan Soundararajan, Tapas K Sengupta, et al.
Transfusion|June 21, 2014
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixaforHenning Schade, Saurabh Chhabra, Yubin Kang, et al.
Head & Neck|January 22, 2009
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancersJohn M Watkins, Keisuke S Shirai, Amy E Wahlquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemiasJeffrey E Lancet, Vu H Duong, Elliott F Winton, et al.
Blood Advances|October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapyGeoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 12, 2013
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratificationLuciano J Costa, Elizabeth J Nista, Francis K Buadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Experimental Hematology|September 30, 2009
Hematopoietic stem cell origin of human fibroblasts: cell culture studies of female recipients of gender-mismatched stem cell transplantation and patients with chronic myelogenous leukemiaKeisuke Shirai, Yasuhiko Sera, William Bulkeley, et al.
Transfusion|March 12, 2011
Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft functionErin T Alexander, Jeanne A Towery, Ashley N Miller, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2015
Elevation of c-MYC disrupts HLA class II-mediated immune recognition of human B cell tumorsJason M God, Christine Cameron, Janette Figueroa, et al.
Blood|December 21, 2006
Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNAYoko Otake, Sridharan Soundararajan, Tapas K Sengupta, et al.
Transfusion|June 21, 2014
Similar dynamics of intraapheresis autologous CD34+ recruitment and collection efficiency in patients undergoing mobilization with or without plerixaforHenning Schade, Saurabh Chhabra, Yubin Kang, et al.
Head & Neck|January 22, 2009
Toxicity and survival outcomes of hyperfractionated split-course reirradiation and daily concurrent chemotherapy in locoregionally recurrent, previously irradiated head and neck cancersJohn M Watkins, Keisuke S Shirai, Amy E Wahlquist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2011
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemiasJeffrey E Lancet, Vu H Duong, Elliott F Winton, et al.
Blood Advances|October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapyGeoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 12, 2013
Prediction of poor mobilization of autologous CD34+ cells with growth factor in multiple myeloma patients: implications for risk-stratificationLuciano J Costa, Elizabeth J Nista, Francis K Buadi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemiaGary J Schiller, Susan M O'Brien, Arnaud Pigneux, et al.
Pageof 5